Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.407 EUR | -0.73% | -0.24% | -.--% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-03 | AIB buys back EUR999 million worth of shares from Irish government | AN |
Sales 2024 * | 4.54B 4.89B 391B | Sales 2025 * | 4.33B 4.66B 372B | Capitalization | 12.07B 13B 1,038B |
---|---|---|---|---|---|
Net income 2024 * | 1.74B 1.87B 150B | Net income 2025 * | 1.54B 1.66B 132B | EV / Sales 2024 * | 2.66 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.79 x |
P/E ratio 2024 * |
7.01
x | P/E ratio 2025 * |
7.29
x | Employees | - |
Yield 2024 * |
5.99% | Yield 2025 * |
6.35% | Free-Float | 67.47% |
Latest transcript on AIB Group plc
1 day | -0.73% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 31/12/15 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 31/08/13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 18/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 21/01/21 |
James Pettigrew
CHM | Chairman | 65 | 27/10/21 |
Basil Geoghegan
BRD | Director/Board Member | - | 03/09/19 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.85% | 571B | |
+14.20% | 301B | |
+18.59% | 252B | |
+25.74% | 216B | |
+21.29% | 183B | |
+25.50% | 170B | |
+9.52% | 162B | |
+5.28% | 146B | |
-15.88% | 131B |
- Stock Market
- Equities
- A5G Stock
- AIBG Stock